Suicide gene-type I interferon expression vector, application thereof and gene modified human mesenchymal stem cell

By combining a suicide gene-type I interferon expression vector with a screening gene system, the problem of limited efficacy of IFNβ gene-modified human mesenchymal stem cells in tumor treatment was solved. This achieved efficient expression and stable control of type I interferon, enhancing the therapeutic effect on tumors and avoiding inflammatory responses.

CN118910167APending Publication Date: 2024-11-08WUXI HUATAI INNOVATIVE PHARM TECH RES INST CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310503772.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing technologies, human mesenchymal stem cells modified with the IFNβ gene have limited inhibitory effects on tumor proliferation and promote apoptosis. Furthermore, the suicide gene system has not been applied to human mesenchymal stem cells, making it impossible to effectively control gene expression and avoid inflammatory responses.

Method used

A suicide gene-type I interferon expression vector was designed. The nucleotide sequences of a suicide gene (such as FKBP-CASP9) and a type I interferon protein were linked through a lentiviral system, and a selection gene (such as glutamine synthase) was introduced. Type I interferon was stably expressed in human mesenchymal stem cells. The expression of the suicide gene was induced by a small molecule drug to control apoptosis. The stability of the gene modification was ensured by combining a non-antibiotic drug screening system.

Benefits of technology

This study achieved efficient expression of type I interferon in human mesenchymal stem cells, significantly enhancing the therapeutic effect on tumors, while avoiding the inflammatory response caused by excessive interferon expression, thus ensuring the stability and safety of gene modification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004214826220000141
    Figure BDA0004214826220000141
  • Figure BDA0004214826220000161
    Figure BDA0004214826220000161
  • Figure BDA0004214826220000241
    Figure BDA0004214826220000241
Patent Text Reader

Abstract

The invention relates to the technical field of genetic engineering, and particularly discloses a suicide gene-type I interferon expression vector, application thereof and a genetically modified human mesenchymal stem cell. The suicide gene-I type interferon expression vector comprises a suicide gene and a nucleotide sequence for coding I type interferon protein; the suicide gene and the nucleotide sequence for coding the I-type interferon protein are connected through the nucleotide sequence for coding the connecting peptide. The invention also discloses an application of the suicide gene-I type interferon expression vector in human mesenchymal stem cells, and particularly discloses a gene modified human mesenchymal stem cell. The human mesenchymal stem cell modified by the gene expresses any one or more of IFN (interferon) alpha 2a, IFN alpha 2b, IFN alpha 2s and IFN beta. The human mesenchymal stem cells genetically modified by the suicide gene-type I interferon expression vector provided by the invention can efficiently express the human type I interferon, and have a relatively good treatment effect on tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of genetic engineering, and more specifically, to a suicide gene-type I interferon expression vector and its application, and genetically modified human mesenchymal stem cells. Background Art

[0002] Human mesenchymal stem cells (MSCs) are a type of multipotent stem cell with the greatest potential for clinical application. They are a research branch of stem cells and exist in a variety of tissues (such as bone marrow, umbilical cord blood, umbilical cord tissue, placental tissue, adipose tissue, etc.). Studies have shown that human mesenchymal stem cells can be directed to chemotaxis to sites of inflammatory damage in the body and participate in tissue damage repair and disease treatment. Therefore, human mesenchymal stem cells have the advantage of being a drug delivery carrier. Human mesenchymal stem cells can be genetically modified to carry specific genes, chemotaxis to the disease microenvironment, and exert a therapeutic effect on the disease by expressing and secreting key molecules encoded by related genes.

[0003] Interferon (IFN) is a broad-spectrum antiviral agent that has inhibitory effects on both RNA and DNA viruses. It can also inhibit tumor cell proliferation, promote tumor cell apoptosis, and inhibit tumor angiogenesis. Depending on the receptors involved in the transmission of interferon information, interferon can be divided into type I interferon and type II interferon. Type I interferon is currently the main force in clinical antiviral treatment. Type I interferon is divided into two categories: IFNα and IFNβ, which are mainly secreted by immune cells (NK cells, B cells, T cells, etc.).

[0004] Human mesenchymal stem cells are modified with target genes using lentiviral vectors to obtain engineered cells expressing interferon genes, which can be used to treat solid tumors and infectious diseases. At present, IFNβ gene-modified human mesenchymal stem cells have shown significant inhibitory proliferation and apoptosis-promoting effects on a variety of tumors, such as prostate cancer, breast cancer, and lung cancer, but the above-mentioned inhibitory proliferation and apoptosis-promoting effects are limited, and there are currently no cases involving the use of IFNα gene-modified human mesenchymal stem cells.

[0005] Suicide gene systems can be derived from gene sequences encoding enzymes of viruses or bacteria, which catalyze the conversion of non-toxic drug precursors into cytotoxic substances, thereby killing cells carrying the gene. Another type of suicide gene system is to use non-therapeutic dimer chemical mutagens to induce dimerization of mutated FK506 binding proteins and activate cascade apoptosis-related gene expression, thereby killing cells carrying the gene. Suicide gene systems are mostly used as anti-tumor gene therapy techniques to kill target tumor cells after being directly introduced into tumor cells. The regulation of gene-modified cells by suicide gene systems can also be used as one of the safety measures for gene therapy, but it has only been tried for immune cell therapy such as CAR-T, by inducing cell apoptosis and controlling the toxic effects caused by the inflammatory factor storm in the body caused by immune cell therapy. At present, there has been no case of using suicide gene systems to control the expression of specific proteins by gene-modified human mesenchymal stem cells. Summary of the invention

[0006] The present application provides a suicide gene-type I interferon expression vector and its application, and gene-modified human mesenchymal stem cells. The suicide gene-type I interferon gene-modified human mesenchymal stem cells can efficiently express human type I interferon and have a good therapeutic effect on tumors.

[0007] In the first aspect, the present application provides a suicide gene-type I interferon expression vector, which adopts the following technical solution:

[0008] A suicide gene-type I interferon expression vector comprises a suicide gene and a nucleotide sequence encoding a type I interferon protein; the suicide gene and the nucleotide sequence encoding the type I interferon protein are connected via a nucleotide sequence encoding a connecting peptide.

[0009] In a specific embodiment, the suicide gene and the nucleotide sequence encoding the type I interferon protein (abbreviated as: type I interferon sequence) in the suicide gene-type I interferon expression vector can be connected in the form of suicide gene-connector peptide-type I interferon sequence.

[0010] In a specific embodiment, the connection mode of the suicide gene and the type I interferon sequence in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-suicide gene.

[0011] Preferably, the suicide gene is any one or more of a nucleotide sequence encoding FKBP-CASP9 and a nucleotide sequence encoding HSVTK.

[0012] Among them, FKBP-CASP9 is the gene sequence of the fusion protein of human Caspase-9 and human FK506 binding protein 1A (FKBP1A). Tacrolimus analogs (Rimiducid) AP1903 or AP20187 can be used as chemical inducers of dimerization. By cross-linking the F36V variant of the FKBP12 (FKBP12-F36V) domain as a dimer, it mediates the conditional dimerization of inducible human Caspase-9, and then activates Caspase3, 6 and 7, leading to apoptosis of cells expressing the fusion protein.

[0013] HSVTK is the herpes simplex virus thymidine kinase gene sequence. HSVTK can encode thymidine kinase, and thymidine kinase can phosphorylate a variety of nucleotide analogs. The phosphorylated nucleotide analogs can terminate the extension of the 3'-OH terminal base of the DNA chain, thereby terminating the DNA replication process and leading to cell apoptosis. For example, the sequence code of HSVTK can be Gene ID: 270337.

[0014] In a specific embodiment, the connection mode of the suicide gene and the type I interferon sequence in the suicide gene-type I interferon expression vector can be: FKBP-CASP9-connecting peptide-type I interferon sequence.

[0015] In a specific embodiment, the connection mode of the suicide gene and the type I interferon sequence in the suicide gene-type I interferon expression vector can be: HSVTK-connecting peptide-type I interferon sequence.

[0016] In a specific embodiment, the connection mode of the suicide gene and the type I interferon sequence in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-FKBP-CASP9.

[0017] In a specific embodiment, the connection mode of the suicide gene and the type I interferon sequence in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-HSVTK.

[0018] Preferably, the expression vector further comprises a screening gene, and the screening gene is connected to the suicide gene and / or the nucleotide sequence encoding the type I interferon protein via the nucleotide sequence encoding the connecting peptide.

[0019] In a specific embodiment, the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be connected in the following manner: suicide gene-connecting peptide-type I interferon sequence-connecting peptide-screening gene.

[0020] In a specific embodiment, the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be connected in the following manner: screening gene-connecting peptide-suicide gene-connecting peptide-type I interferon sequence.

[0021] In a specific embodiment, the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be connected in the following manner: type I interferon sequence-connecting peptide-suicide gene-connecting peptide-screening gene.

[0022] In a specific embodiment, the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be connected in the following manner: screening gene-connecting peptide-type I interferon sequence-connecting peptide-suicide gene.

[0023] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: suicide gene-connector peptide-screening gene-connector peptide-type I interferon sequence.

[0024] In a specific embodiment, the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be connected in the following manner: type I interferon sequence-connecting peptide-screening gene-connecting peptide-suicide gene.

[0025] Preferably, the screening gene is a nucleotide sequence encoding glutamine synthetase.

[0026] Glutamine synthetase (GS) is an enzyme in the body that uses other substances to synthesize glutamine. The nucleotide sequence encoding glutamine synthetase was transduced into human mesenchymal stem cells using a lentiviral system. During the culture of human mesenchymal stem cells, if the GS inhibitor methionine sulfhydrylamine (MSX) is added, the expression of the endogenous GS gene can be inhibited. Only when the inserted exogenous GS gene is amplified can it survive. Therefore, under the drug pressure of MSX, the resulting MSX-resistant cell line is a cell line with high-level expression of the GS gene.

[0027] At the same time, the nucleotide sequence introduced into human mesenchymal stem cells using the lentiviral system also encodes a suicide gene, such as FKBP-CASP9. Therefore, under the drug pressure of MSX, the anti-MSX cell line obtained is also a cell line with high expression of the target gene FKBP-CASP9-2A-IFNα2a, so it is possible to obtain a screening strain with stable expression of both the suicide gene and the screening gene.

[0028] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: suicide gene-connector peptide-type I interferon sequence-connector peptide-GS.

[0029] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: GS-connecting peptide-suicide gene-connecting peptide-type I interferon sequence.

[0030] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-suicide gene-connecting peptide-GS.

[0031] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: GS-connecting peptide-type I interferon sequence-connecting peptide-suicide gene.

[0032] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: suicide gene-connector peptide-GS-connector peptide-type I interferon sequence.

[0033] In a specific embodiment, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-GS-connecting peptide-suicide gene.

[0034] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: FKBP-CASP9-connecting peptide-type I interferon sequence-connecting peptide-GS.

[0035] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: GS-connecting peptide-FKBP-CASP9-connecting peptide-type I interferon sequence.

[0036] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-FKBP-CASP9-connecting peptide-GS.

[0037] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: GS-connecting peptide-type I interferon sequence-connecting peptide-FKBP-CASP9.

[0038] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: FKBP-CASP9-connecting peptide-GS-connecting peptide-type I interferon sequence.

[0039] In a specific embodiment, when the suicide gene is FKBP-CASP9, the connection mode of the suicide gene, type I interferon sequence and screening gene in the suicide gene-type I interferon expression vector can be: type I interferon sequence-connecting peptide-GS-connecting peptide-FKBP-CASP9.

[0040] Preferably, the nucleotide sequence encoding glutamine synthetase can be replaced by a nucleotide sequence encoding an antibiotic resistance gene; the antibiotic resistance gene is any one or more of a puromycin resistance (Puro) gene, a neomycin resistance (Neo) gene, a hygromycin resistance (Hygro B) gene and a blasticidin resistance (Bsd) gene.

[0041] The nucleotide sequence encoding the antibiotic resistance gene is transduced into human mesenchymal stem cells using a lentiviral system. During the culture of human mesenchymal stem cells, if antibiotics are added, cells that do not express the corresponding antibiotic resistance gene will die. Only when the inserted corresponding antibiotic resistance gene is expressed can human mesenchymal stem cells survive. Therefore, under the pressure of antibiotics, the obtained cell line is a cell line with a high level of expression of the antibiotic resistance gene. For example, when the screening gene is a puromycin resistance gene, during the culture of human mesenchymal stem cells, if puromycin is added, cells that do not express the puromycin resistance gene will die. Only when the inserted puromycin resistance gene is expressed can human mesenchymal stem cells survive, and the obtained cell line is a cell line with a high level of expression of the puromycin resistance gene.

[0042] At the same time, the nucleotide sequence introduced into human mesenchymal stem cells using the lentiviral system also encodes a suicide gene, such as FKBP-CASP9. Therefore, under the pressure of antibiotics, the cell line with high expression of the gene resistant to the antibiotic is also a cell line with high expression of the target gene FKBP-CASP9-2A-IFNα2a, so it is possible to obtain a screening strain in which both the suicide gene and the screening gene are stably expressed. For example, when the screening gene is a puromycin-resistant gene, under the pressure of puromycin, the cell line with high expression of the puromycin-resistant gene is also a cell line with high expression of the target gene FKBP-CASP9-2A-IFNα2a. In addition, when the screening gene is a neomycin-resistant gene, a hygromycin-resistant gene, and a blasticidin-resistant gene, the screening principle of the obtained cell line is the same as when the screening gene is a puromycin-resistant gene.

[0043] Preferably, the nucleotide sequence encoding the connecting peptide is any one or more of the nucleotide sequences encoding P2A, T2A, E2A, F2A, and IRES.

[0044] Preferably, the front end of the nucleotide sequence encoding the type I interferon protein is immediately followed by a nucleotide sequence encoding a secretion signal peptide; the nucleotide sequence encoding the secretion signal peptide comprises the nucleotide sequence shown in SEQ ID NO 1.

[0045] The nucleotide sequence of the secretory signal peptide provided by the present application comprises the nucleotide sequence shown in SEQ ID NO 1, which is used to guide the secretory expression of type I interferon protein in human mesenchymal stem cells. The secretory signal peptide is obtained by optimizing and transforming the starting secretory signal peptide sequence in the CDS region of the type I interferon gene. Compared with the secretory signal peptide before optimization and transformation, the secretory signal peptide provided by the present application can effectively promote the secretory expression of type I interferon protein and improve the secretion efficiency of type I interferon protein.

[0046] Preferably, the nucleotide sequence encoding type I interferon protein includes any one or more of the nucleotide sequences encoding IFNα protein and IFNβ protein.

[0047] Preferably, the nucleotide sequence encoding the type I interferon protein includes any one or more of the nucleotide sequences encoding IFNα2a protein, IFNα2b protein, IFNα2s protein, and IFNβ protein.

[0048] Based on the lentiviral gene transfection system, an expression vector carrying a suicide gene and / or a screening gene and a target gene (type I interferon gene) is constructed. The expression vector is used to perform plasmid transfection in cells, and a lentivirus with a suicide gene-type I interferon-screening gene sequence is obtained. Human mesenchymal stem cells are infected with lentivirus to obtain human mesenchymal stem cells after gene transduction. The type I interferon gene is transcribed and expressed in human mesenchymal stem cells to obtain type I interferon protein.

[0049] In a specific embodiment, the IFNα protein can be an IFNα2a protein.

[0050] In a specific embodiment, the IFNα protein may be an IFNα2b protein.

[0051] In a specific embodiment, the IFNα protein may be an IFNα2s protein.

[0052] In a specific embodiment, the IFNβ protein can be an IFNβ1 protein.

[0053] In a specific embodiment, the nucleotide sequence encoding IFNα2a comprises the nucleotide sequence shown as SEQ ID NO 2.

[0054] In a specific embodiment, the nucleotide sequence encoding IFNα2b comprises the nucleotide sequence shown as SEQ ID NO 3.

[0055] In a specific embodiment, the nucleotide sequence encoding IFNα2s comprises the nucleotide sequence shown as SEQ ID NO 4.

[0056] In a specific embodiment, the nucleotide sequence encoding IFNβ1 comprises the nucleotide sequence shown in SEQ ID NO 5.

[0057] In a specific embodiment, the expression vector is pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a plasmid.

[0058] In a specific embodiment, the expression vector is pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b plasmid.

[0059] In a specific embodiment, the expression vector is pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s plasmid.

[0060] In a specific embodiment, the expression vector is pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 plasmid.

[0061] In a specific embodiment, the expression vector is pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS plasmid.

[0062] In a specific embodiment, the expression vector is pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS plasmid.

[0063] In a specific embodiment, the expression vector is pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS plasmid.

[0064] In a specific embodiment, the expression vector is pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS plasmid.

[0065] In a second aspect, the present application provides the above-mentioned suicide gene-type I interferon expression vector for use in a third-generation lentiviral packaging system, a second-generation lentiviral packaging system or an adeno-associated virus AAV packaging system for virus packaging.

[0066] In a third aspect, the present application provides the use of the above suicide gene-type I interferon expression vector in human mesenchymal stem cells.

[0067] In a fourth aspect, the present application provides a genetically modified human mesenchymal stem cell, using the following technical solution:

[0068] A genetically modified human mesenchymal stem cell, wherein the human mesenchymal stem cell expresses any one or more of IFNα2a, IFNα2b, IFNα2s, and IFNβ1.

[0069] Preferably, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a, FKBP-CASP9-2A-IFNα2b, FKBP-CASP9-2A-IFNα2s or FKBP-CASP9-2A-IFNβ1.

[0070] Preferably, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a-IRES-GS, FKBP-CASP9-2A-IFNα2b-IRES-GS, FKBP-CASP9-2A-IFNα2s-IRES-GS or FKBP-CASP9-2A-IFNβ1-IRES-GS.

[0071] In a specific embodiment, the human mesenchymal stem cells express IFNα2a.

[0072] In a specific embodiment, the human mesenchymal stem cells express IFNα2b.

[0073] In a specific embodiment, the human mesenchymal stem cells express IFNα2s.

[0074] In a specific embodiment, the human mesenchymal stem cells express IFNβ1.

[0075] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a.

[0076] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2b.

[0077] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2s.

[0078] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNβ1.

[0079] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a-IRES-GS.

[0080] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2b-IRES-GS.

[0081] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2s-IRES-GS.

[0082] In a specific embodiment, the human mesenchymal stem cells express FKBP-CASP9-2A-IFNβ1-IRES-GS.

[0083] Preferably, the human mesenchymal stem cells are one or more of human umbilical cord mesenchymal stem cells, human umbilical cord blood mesenchymal stem cells, human adipose mesenchymal stem cells, human bone marrow mesenchymal stem cells, human dental pulp mesenchymal stem cells, human placental mesenchymal stem cells, and human uterine blood mesenchymal stem cells.

[0084] In a fifth aspect, the present application provides the use of the above-mentioned gene-modified human mesenchymal stem cells in the preparation of drugs for treating solid tumors.

[0085] Preferably, the solid tumor includes any one or more of melanoma, colon cancer, ovarian cancer, pancreatic cancer, breast cancer, glioma, prostate cancer, gastric cancer, liver cancer, lung cancer, and kidney cancer.

[0086] The present application provides a genetically modified human mesenchymal stem cell, which can express type I interferon. The genetically modified mesenchymal stem cell can control the expression of interferon, thereby avoiding excessive expression of interferon by human mesenchymal stem cells, thereby avoiding inducing excessive inflammation.

[0087] The genetically modified human mesenchymal stem cells provided in the present application also have a suicide gene system (FKBP-CASP9) introduced. While interferon is expressed, the expression of the suicide gene can be induced by adding clinical small molecule drugs at a specific time to control the apoptosis of human mesenchymal stem cells carrying the gene, thereby achieving control of the excessive expression of interferon in the genetically modified human mesenchymal stem cells. FKBP-CASP9 is a fusion protein gene sequence of human Caspase-9 and human FK506 binding protein 1A (FKBP1A). Tacrolimus analogs (Rimiducid) AP1903 or AP20187 can be used as a chemical inducer of dimerization, and the F36V variant of the cross-linked FKBP12 (FKBP12-F36V) domain is used as a dimer to mediate the conditional dimerization of inducible human Caspase-9, and then activate Caspase3, 6 and 7, leading to apoptosis of cells expressing the fusion protein.

[0088] In addition, a non-antibiotic drug screening system can also be added to ensure that a clinical-grade human mesenchymal stem cell line with genetic modification and stable expression is obtained. The cell culture and growth process requires glutamine (L-glutamine), and glutamine synthetase (GS) converts glutamate and ammonia into glutamine. Animal cells obtain glutamine through this enzymatic reaction. The endogenous GS activity of human mesenchymal stem cells is low, and it is impossible to synthesize enough glutamine, so glutamine needs to be added to the culture medium. In this application, the exogenous human GS gene and the FKBP-CASP9-2A-IFNα2a target protein gene sequence are simultaneously inserted into the expression vector and transduced into human mesenchymal stem cells through a lentiviral system. During the culture process, if the GS inhibitor methionine thioxamine (MSX) is added, the expression of the endogenous GS gene can be inhibited, and only when the inserted exogenous GS gene is amplified can it survive. Therefore, under the drug pressure of MSX, the anti-MSX cell line obtained is a high-level expression of the GS gene, and it is also a high-level expression of the target gene FKBP-CASP9-2A-IFNα2a, and a stable expression screening strain is obtained.

[0089] In a specific embodiment, the method for preparing genetically modified human mesenchymal stem cells provided in the present application specifically comprises the following steps:

[0090] 1) Based on the lentiviral gene transfection system, construct a clinical small molecule-induced suicide gene-type I interferon expression vector plasmid;

[0091] 2) performing plasmid transfection and obtaining a lentivirus carrying a suicide gene-type I interferon gene sequence;

[0092] 3) Using lentivirus to infect human mesenchymal stem cells to obtain gene-modified human mesenchymal stem cells.

[0093] In a specific embodiment, the method for preparing genetically modified human mesenchymal stem cells provided in the present application specifically comprises the following steps:

[0094] 1) Based on the lentiviral gene transfection system, construct a clinical small molecule-induced suicide gene-type I interferon-screening gene expression vector plasmid;

[0095] 2) performing plasmid transfection and obtaining a lentivirus carrying a suicide gene-type I interferon-screening gene sequence;

[0096] 3) Using lentivirus to infect human mesenchymal stem cells to obtain gene-modified human mesenchymal stem cells;

[0097] 4) Through drug screening, a human mesenchymal stem cell line that stably expresses the suicide gene-type I interferon-screening gene sequence is obtained.

[0098] In summary, this application has the following beneficial effects:

[0099] The genetically modified human mesenchymal stem cells provided in this application can stably express interferon. A suicide gene system is also introduced to induce suicide gene expression by adding clinically approved small molecule drugs to avoid excessive expression of interferon by human mesenchymal stem cells, thereby avoiding inducing excessive inflammation. In addition, a non-antibiotic drug screening system is also added to ensure the acquisition of a clinical-grade human mesenchymal stem cell line that is genetically modified and stably expressed.

[0100] The human mesenchymal stem cells modified with the suicide gene-type I interferon gene provided in the present application can efficiently express human type I interferon, and the suicide gene exhibits a good inducible cell apoptosis function. Further, by introducing a screening gene while modifying the suicide gene-type I interferon gene, a screening strain with high-level expression of the screening gene and high-level and stable expression of the suicide gene-type I interferon gene can be screened out.

[0101] The gene-modified human umbilical cord mesenchymal stem cells provided in this application have a good therapeutic effect on mouse tumor models. Compared with human mesenchymal stem cells with IFNβ1 gene, human mesenchymal stem cells with IFNα gene (IFNα2a gene, IFNα2b gene, IFNα2s gene) have better therapeutic effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0102] Figure 1 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a plasmid in Example 1.

[0103] Figure 2 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b plasmid in Example 2.

[0104] Figure 3 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s plasmid in Example 3.

[0105] Figure 4 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 plasmid in Example 4.

[0106] Figure 5 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS plasmid in Example 5.

[0107] Figure 6This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS plasmid in Example 6.

[0108] Figure 7 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS plasmid in Example 7.

[0109] Figure 8 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS plasmid in Example 8. DETAILED DESCRIPTION

[0110] The present application provides a suicide gene-type I interferon expression vector, which includes a suicide gene and a nucleotide sequence encoding a type I interferon protein; the suicide gene and the nucleotide sequence encoding the type I interferon protein are connected by a nucleotide sequence encoding a connecting peptide. Wherein, the nucleotide sequence encoding the type I interferon protein includes any one or more of the nucleotide sequences encoding IFNα protein and IFNβ protein. The suicide gene is any one or more of the nucleotide sequence encoding FKBP-CASP9 and the nucleotide sequence encoding HSVTK. The front end of the nucleotide sequence encoding the type I interferon protein is immediately followed by a nucleotide sequence encoding a secretion signal peptide; the nucleotide sequence encoding the secretion signal peptide includes a nucleotide sequence as shown in SEQ ID NO 1.

[0111] Furthermore, the expression vector further comprises a screening gene, wherein the screening gene is connected to the suicide gene and / or the nucleotide sequence encoding the type I interferon protein through the nucleotide sequence encoding the connecting peptide; the screening gene is a nucleotide sequence encoding glutamine synthetase. The nucleotide sequence encoding glutamine synthetase can be replaced by a nucleotide sequence encoding an antibiotic resistance gene; the antibiotic resistance gene is any one or more of a puromycin resistance gene, a neomycin resistance gene, a hygromycin resistance gene, and a blasticidin resistance gene.

[0112] Furthermore, the nucleotide sequence encoding the connecting peptide is any one or more of the nucleotide sequences encoding P2A, T2A, E2A, F2A, and IRES.

[0113] In addition, the present application also discloses the use of a suicide gene-type I interferon expression vector.

[0114] Specifically, the suicide gene-type I interferon expression vector can be used for virus packaging in a third-generation lentiviral packaging system, a second-generation lentiviral packaging system or an adeno-associated virus AAV packaging system.

[0115] Specifically, the suicide gene-type I interferon expression vector is used in human mesenchymal stem cells.

[0116] The present application provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell expresses any one or more of IFNα2a, IFNα2b, IFNα2s, and IFNβ1. Further, the human mesenchymal stem cell expresses FKBP-CASP9-2A-IFNα2a, FKBP-CASP9-2A-IFNα2b, FKBP-CASP9-2A-IFNα2s or FKBP-CASP9-2A-IFNβ1. Further still, the human mesenchymal stem cell expresses FKBP-CASP9-2A-IFNα2a-IRES-GS, FKBP-CASP9-2A-IFNα2b-IRES-GS, FKBP-CASP9-2A-IFNα2s-IRES-GS or FKBP-CASP9-2A-IFNβ1-IRES-GS.

[0117] The human mesenchymal stem cells are one or more of human umbilical cord mesenchymal stem cells, human umbilical cord blood mesenchymal stem cells, human adipose mesenchymal stem cells, human bone marrow mesenchymal stem cells, human dental pulp mesenchymal stem cells, human placental mesenchymal stem cells and human uterine blood mesenchymal stem cells.

[0118] In addition, the present application also discloses the use of the above-mentioned gene-modified human mesenchymal stem cells.

[0119] Specifically, the gene-modified human mesenchymal stem cells are used in the preparation of a drug for treating solid tumors, wherein the solid tumors include any one or more of melanoma, colon cancer, ovarian cancer, pancreatic cancer, and breast cancer.

[0120] In this application, the nucleotide sequences involved are shown in Table 1.

[0121] Table 1 Nucleotide sequences involved in this application

[0122] Serial number name type sequence 1 Optimized secretion signal peptide DNA SEQ ID NO 1 2 IFNα2a DNA SEQ ID NO 2 3 IFNα2b DNA SEQ ID NO 3 4 IFNα2s DNA SEQ ID NO 4 5 IFNβ1 DNA SEQ ID NO 5 6 FKBP-CASP9 DNA SEQ ID NO 6 7 P2A DNA SEQ ID NO 7 8 EF1α DNA SEQ ID NO 8 9 IRES DNA SEQ ID NO 9 10 GS DNA SEQ ID NO 10

[0123] The present application is further described in detail below in conjunction with embodiments and comparative examples.

[0124] Examples 1-8

[0125] Example 1

[0126] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2a gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2a gene. The gene sequence encoding the IFNα2a secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0127] The vector plasmid used in this example is the pRRLSIN.cPPT.PGK-GFP.WPRE vector plasmid in the three-plasmid lentiviral system of Addgene.

[0128] The method for preparing the above-mentioned gene-modified human mesenchymal stem cells specifically comprises the following steps:

[0129] (1) Construction of plasmid

[0130] Based on the vector plasmid, the gene sequence in the ORF (Open Reading Frame) expression frame was constructed. Through molecular cloning PCR technology and enzyme digestion reaction, the expression-inducing suicide gene-IFNα gene sequence was added to the vector plasmid ORF expression frame. The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a plasmid was constructed. The composition of the plasmid is shown in the figure below. Figure 1 shown.

[0131] Figure 1 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a plasmid in Example 1.

[0132] Among them, FKBP-CASP9 is the gene sequence of the fusion protein of human Caspase-9 and human FK506 binding protein 1A (FKBP1A). Tacrolimus analogs (Rimiducid) AP1903 or AP20187 can be used as chemical inducers of dimerization. By cross-linking the F36V variant of the FKBP12 (FKBP12-F36V) domain as a dimer, it mediates the conditional dimerization of inducible human Caspase-9, and then activates Caspase3, 6 and 7, leading to apoptosis of cells expressing the fusion protein.

[0133] 2A is a self-cleaving 2A peptide (2A) element, i.e., a connecting peptide, which can connect multiple genes to achieve the purpose of expressing multiple polycistronic genes on a single vector.

[0134] IFNα2a is a human type I interferon 2a subtype gene sequence. In this embodiment, the secretion signal peptide sequence of the gene coding region is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the modified interferon protein is increased by more than 30%.

[0135] (2) Plasmid amplification

[0136] The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) were transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial liquids corresponding to the three plasmids.

[0137] The co-culture conditions are: LB medium (Sigma, specification: L3522-1KG), ampicillin resistance (concentration 20 μg / ml), 200 mL / bottle, culture at 37° C., 220 rpm / min for 16 h.

[0138] (3) Plasmid extraction

[0139] The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a, pMD2G and psPAX2 plasmids were extracted from the amplified Escherichia coli using an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117).

[0140] The operation process is:

[0141] a) Column equilibration step: add 2.5 mL of equilibration solution BL to the adsorption column CP6 (the adsorption column CP6 is placed in a 50 mL collection tube), centrifuge at 8000 rpm (~8228 × g) for 2 min, discard the waste liquid in the collection tube, and put the adsorption column CP6 back into the collection tube;

[0142] b) Take 200 mL of overnight cultured E. coli and add it to a centrifuge tube. Centrifuge at room temperature at 8000 rpm (~8228 × g) for 3 min. Collect the culture solution and remove the supernatant as much as possible. Leave the bacterial precipitate in the centrifuge tube.

[0143] c) Add 8 mL of solution P1 (with RNase A added) to the centrifuge tube containing the bacterial cell pellet, and use a pipette or vortex oscillator to completely lyse the suspended bacterial cell pellet;

[0144] d) Add 8 mL of solution P2 to the centrifuge tube, gently invert it upside down 6-8 times, and leave it at room temperature for 5 minutes;

[0145] e) Add 8 mL of solution P4 to the centrifuge tube, and immediately and gently turn it upside down 6-8 times to mix thoroughly until white dispersed flocculent precipitates appear in the solution; then place it at room temperature for 10 minutes, centrifuge it at 8000 rpm (~8228×g) for 5-10 minutes, centrifuge it to make the white precipitate centrifuge to the bottom of the tube, carefully pour all the solution into the filter CS1, slowly push the push handle to filter, and collect the filtrate in a clean 50 mL collection tube;

[0146] f) adding 0.3 times the volume of isopropanol to the filtrate, mixing by inversion, and transferring to adsorption column CP6, which was placed in a 50 ml collection tube;

[0147] g) Centrifuge at 8000 rpm (~8228×g) for 2 min at room temperature, discard the waste liquid in the collection tube, and put the adsorption column CP6 back into the 50 ml collection tube;

[0148] h) Add 10 mL of rinse solution PW (with anhydrous ethanol) to the adsorption column CP6, centrifuge at 8000 rpm (~8228×g) for 2 min, discard the waste liquid in the collection tube, and put the adsorption column CP6 back into the 50 mL collection tube;

[0149] i) Repeat step 8;

[0150] j) Add 3 mL of anhydrous ethanol to the adsorption column CP6, centrifuge at 8000 rpm (~8228×g) for 2 min at room temperature, discard the waste liquid, and put the adsorption column CP6 back into the 50 mL collection tube;

[0151] k) Centrifuge at 8000 rpm (~8228×g) at room temperature for 5 min, place the adsorption column CP6 in a clean 50 mL collection tube, add 1-2 mL of eluent TB to the middle part of the adsorption membrane of the adsorption column CP6, let it stand at room temperature for 5 min, and then centrifuge at 8000 rpm (~8228×g) at room temperature for 2 min; transfer all the eluent in the 50 mL centrifuge tube to a clean 1.5 mL centrifuge tube and store it at -20°C.

[0152] (4) Virus packaging

[0153] The plasmid was transfected into 293T cell line (ATCC) using liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus.

[0154] Steps:

[0155] a) On D0, 293T cells were seeded in 6-well plates, with 5×10 5 The next day, the cell confluence was about 70-80%, and PBS was washed twice, and 1 mL of serum-free DMEM was added;

[0156] b) Prepare the raw materials according to the instructions of the Lipo2000 transfection kit, as shown in Table 2.

[0157] Table 2 Raw materials required for virus packaging

[0158]

[0159] c) Mix the plasmid mixture (pMD2G, pSPAX2 and pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2a) with Lipo2000 and let stand for 20 min;

[0160] d) Add to 6-well plate, and replace with normal culture medium (DMEM high-glucose complete medium containing 10% FBS; ChemicalBook) after 6 h;

[0161] e) After 48 h, the supernatant was collected, centrifuged at 600 × g for 10 minutes, and filtered through a 0.45 μM or 0.22 μM filter to remove cells;

[0162] f) using ultra-100K filter membrane for ultracentrifugation to enrich the virus (4000 rpm, 30 min) and concentrate 20 times to obtain a lentiviral concentrate;

[0163] (5) Viral infection

[0164] Human umbilical cord mesenchymal stem cells (cell bank of Type Culture Collection Committee of Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2a.

[0165] Steps:

[0166] a) On D0, human umbilical cord mesenchymal stem cells (P2 generation) were seeded in 6-well plates with a confluence of 70-80%;

[0167] b) On D1, according to the 6-well plate specification system, add the corresponding virus (1.5 mL complete DMEM medium + 200 ul lentivirus concentrate), and add polybrene (5-10 μg / mL) for infection for 10-24 hours, and change the medium (replace with DMEM high-glucose complete medium containing 10% FBS; ChemicalBook);

[0168] c) After 48 hours, the supernatant or cells can be collected to detect the expression level of IFNα2a protein. Protein expression was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared genetically modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2a.

[0169] Example 2

[0170] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2b gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2b gene. The gene sequence encoding the IFNα2b secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0171] The differences between this embodiment and embodiment 1 are as follows, and the rest are the same as embodiment 1.

[0172] Step (1) constructing a plasmid: constructing a pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b plasmid, the composition of which is shown in the figure below: Figure 2 shown.

[0173] Figure 2 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b plasmid in Example 2.

[0174] Among them, IFNα2b is a human type I interferon 2b subtype gene sequence. In this embodiment, the secretion signal peptide sequence of the gene coding region is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the modified interferon protein is increased by more than 30%.

[0175] Step (2) plasmid amplification: The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0176] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0177] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 3.

[0178] Table 3 Raw materials required for virus packaging

[0179] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2b 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0180] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Committee for Type Culture Collection of the Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2b.

[0181] Detection of IFNα2b protein expression level. The expression of IFNα2b protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared gene-modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2b.

[0182] Example 3

[0183] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2s gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2s gene. The gene sequence encoding the IFNα2s secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0184] The differences between this embodiment and embodiment 1 are as follows, and the rest are the same as embodiment 1.

[0185] Step (1) constructing a plasmid: constructing a pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s plasmid, the composition of which is shown in the figure below: Figure 3 shown.

[0186] Figure 3 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s plasmid in Example 3.

[0187] Among them, IFNα2s is a partial codon replacement optimization of the gene sequence of human type I interferon 2b subtype, which prolongs the half-life of the protein. In this embodiment, the secretion signal peptide sequence of the gene coding region is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the interferon protein after the modification is increased by more than 30%.

[0188] Step (2) plasmid amplification: The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0189] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNα2s, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0190] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 4.

[0191] Table 4 Raw materials required for virus packaging

[0192]

[0193] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Committee for Type Culture Collection of the Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2s.

[0194] Detection of IFNα2s protein expression level. The expression of IFNα2s protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared gene-modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2s.

[0195] Example 4

[0196] This embodiment provides a gene-modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNβ1 gene through a lentiviral system to obtain the human mesenchymal stem cell with the IFNβ1 gene.

[0197] The differences between this embodiment and embodiment 1 are as follows, and the rest are the same as embodiment 1.

[0198] Step (1) constructing a plasmid: constructing a pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 plasmid, the composition of which is shown in the figure below: Figure 4 shown.

[0199] Figure 4 This is a composition diagram of the pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 plasmid in Example 4.

[0200] Among them, IFNβ1 is a type of IFNβ.

[0201] Step (2) plasmid amplification: The pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0202] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0203] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 5.

[0204] Table 5 Raw materials required for virus packaging

[0205] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.PGK-FKBP-CASP9-2A-IFNβ1 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0206] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Committee for Type Culture Collection of the Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNβ1.

[0207] Detection of IFNβ1 protein expression level. The expression of IFNβ1 protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared genetically modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNβ1.

[0208] Example 5

[0209] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2a gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2a gene. The gene sequence encoding the IFNα2a secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0210] The differences between this embodiment and embodiment 1 are as follows, and the rest are the same as embodiment 1.

[0211] Step (1) constructing a plasmid: by molecular cloning PCR technology and restriction digestion reaction, the expression-inducing suicide gene-IFNa-screening gene sequence is added to the vector plasmid ORF expression frame, and at the same time, the human PGK promoter is replaced with the human EF1α promoter to construct the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS plasmid. The composition of the plasmid is shown in the figure below: Figure 5 shown.

[0212] Figure 5 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS plasmid in Example 5.

[0213] Among them, IRES is the ribosome entry site sequence, that is, the connecting peptide.

[0214] IFNα2a is a human type I interferon 2a subtype gene sequence. In this embodiment, the secretion signal peptide sequence of the gene coding region is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the modified interferon protein is increased by more than 30%.

[0215] GS is glutamine synthetase (GS). After GS transcriptional expression is mediated by IRES, it plays a screening gene function.

[0216] The cell culture and growth process requires glutamine (L-glutamine). Glutamine synthetase (GS) converts glutamate and ammonia into glutamine. Animal cells obtain glutamine through this enzymatic reaction. Human mesenchymal stem cells have low endogenous GS activity and cannot synthesize enough glutamine, so glutamine needs to be added to the culture medium.

[0217] In this example, the exogenous human GS gene and the FKBP-CASP9-2A-IFNα2a target protein gene sequence were simultaneously inserted into the expression vector and transduced into human umbilical cord mesenchymal stem cells through a lentiviral system. During the culture process, if the GS inhibitor methionine thioxamine (MSX) is added, the expression of the endogenous GS gene can be inhibited, and only when the inserted exogenous GS gene is amplified can it survive. Therefore, under the drug pressure of MSX, the anti-MSX cell line obtained is a high-level expression of the GS gene, and also a high-level expression of the target gene FKBP-CASP9-2A-IFNα2a, and a stable expression screening strain is obtained.

[0218] Step (2) plasmid amplification: The pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0219] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0220] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 6.

[0221] Table 6 Raw materials required for virus packaging

[0222] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2a-IRES-GS 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0223] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2a-IRES-GS.

[0224] Detection of IFNα2a protein expression level. The expression of IFNα2a protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared genetically modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2a-IRES-GS.

[0225] Step (6) Screening of stable expression cell lines.

[0226] During the cell culture process of completed lentiviral gene transduction, glutamine-free medium was used, and 1000mM MSX was added to inhibit endogenous GS expression. The culture was maintained for 15 days, and intolerant cell death was observed. The surviving cells were passaged when the confluence reached 90-95%, and at least two generations of cells were cultured at a high concentration of MSX to satisfy the purification and screening of FKBP-CASP9-2A-IFNα2a expressing cells, and then frozen for library construction, followed by long-term culture in 50mM MSX.

[0227] Example 6

[0228] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2b gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2b gene. The gene sequence encoding the IFNα2b secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0229] The differences between this embodiment and embodiment 5 are as follows, and the rest are the same as embodiment 5.

[0230] Step (1) constructing a plasmid: constructing a plasmid pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS. The composition of the plasmid is shown in the figure below. Figure 6 shown.

[0231] Figure 6 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS plasmid in Example 6.

[0232] Among them, IFNα2b is a human type I interferon 2b subtype gene sequence. In this embodiment, the secretion signal peptide sequence of the gene coding region is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the modified interferon protein is increased by more than 30%.

[0233] Step (2) plasmid amplification: The pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0234] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0235] Step (4) Virus packaging: A liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) was used to perform plasmid transfection in a 293T cell line (ATCC) and harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 7.

[0236] Table 7 Raw materials required for virus packaging

[0237] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2b-IRES-GS 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0238] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Committee for Type Culture Collection of the Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2b-IRES-GS.

[0239] Detection of IFNα2b protein expression level. The expression of IFNα2b protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared gene-modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2b-IRES-GS.

[0240] Step (6) Screening of stable expression cell lines.

[0241] During the cell culture process of completed lentiviral gene transduction, glutamine-free medium was used, and 1000mM MSX was added to inhibit endogenous GS expression. The culture was maintained for 15 days, and intolerant cell death was observed. The surviving cells were passaged when the confluence reached 90-95%, and at least two generations of cells were cultured at a high concentration of MSX to satisfy the purification and screening of FKBP-CASP9-2A-IFNα2b expressing cells, and then frozen for library construction, followed by long-term culture in 50mM MSX.

[0242] Example 7

[0243] This embodiment provides a genetically modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNα2s gene through a lentiviral system to obtain a human mesenchymal stem cell carrying the IFNα2s gene. The gene sequence encoding the IFNα2s secretion signal peptide is an optimized and modified sequence, specifically the nucleotide sequence shown in SEQ ID NO 1.

[0244] The differences between this embodiment and embodiment 5 are as follows, and the rest are the same as embodiment 5.

[0245] Step (1) constructing a plasmid: constructing a plasmid pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS. The composition of the plasmid is shown in the figure below. Figure 7 shown.

[0246] Figure 7 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS plasmid in Example 7.

[0247] Among them, IFNα2s is a human type I interferon 2b subtype gene sequence partial codon replacement optimization, which prolongs the half-life of the protein. In this embodiment, the gene secretion signal peptide sequence is optimized and modified to improve the secretion efficiency of the interferon protein. Compared with the secretion efficiency of the interferon protein before the modification, the secretion efficiency of the modified interferon protein is increased by more than 30%.

[0248] Step (2) plasmid amplification: The pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0249] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0250] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 8.

[0251] Table 8 Raw materials required for virus packaging

[0252] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNα2s-IRES-GS 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0253] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of Type Culture Collection Committee of Chinese Academy of Sciences) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNα2s-IRES-GS.

[0254] Detection of IFNα2s protein expression level. The expression of IFNα2s protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared genetically modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNα2s-IRES-GS.

[0255] Step (6) Screening of stable expression cell lines.

[0256] During the cell culture process of completed lentiviral gene transduction, glutamine-free medium was used, and 1000mM MSX was added to inhibit endogenous GS expression. The culture was maintained for 15 days, and intolerant cell death was observed. The surviving cells were passaged when the confluence reached 90-95%, and at least two generations of cells were cultured at a high concentration of MSX to meet the purification and screening of FKBP-CASP9-2A-IFNα2s expressing cells, and then frozen for library construction, followed by long-term culture with 50mM MSX.

[0257] Example 8

[0258] This embodiment provides a gene-modified human mesenchymal stem cell. The human mesenchymal stem cell is introduced with the IFNβ1 gene through a lentiviral system to obtain the human mesenchymal stem cell with the IFNβ1 gene.

[0259] The differences between this embodiment and embodiment 5 are as follows, and the rest are the same as embodiment 5.

[0260] Step (1) constructing a plasmid: by molecular cloning PCR technology and restriction enzyme digestion reaction, the expression-inducing suicide gene-IFNβ-screening gene sequence is added to the vector plasmid ORF expression frame, and at the same time, the human PGK promoter is replaced with the human EF1α promoter to construct the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS plasmid. The composition of the plasmid is shown in the figure below. Figure 8 shown.

[0261] Figure 8 This is a composition diagram of the pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS plasmid in Example 8.

[0262] Among them, IFNβ1 is a type of IFNβ.

[0263] Step (2) plasmid amplification: The pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS plasmid, as well as the pMD2G and psPAX2 plasmids obtained in step (1) are transformed into competent E. coli, cultured and amplified to obtain E. coli bacterial cultures corresponding to the three plasmids.

[0264] Step (3) plasmid extraction: Use an endotoxin-free plasmid extraction kit (Tiangen Biochemical, DP117) to extract pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A–IFNβ1-IRES-GS, pMD2G and psPAX2 plasmids from the amplified E. coli.

[0265] Step (4) Virus packaging: Plasmid transfection was performed in 293T cell line (ATCC) using a liposome transfection kit (Lipo2000 transfection kit, Invitrogen, catalog number: 11668019) to harvest the virus. Raw materials were prepared according to the instructions of the Lipo2000 transfection kit, as shown in Table 9.

[0266] Table 9 Raw materials required for virus packaging

[0267] Serial number type Dosage 1 pMD2G 1 μg 2 pSPAX2 3μg 3 pRRLSIN.cPPT.EF1α-FKBP-CASP9-2A-IFNβ1-IRES-GS 4 μg 4 DMEM (serum-free) 200μL 5 Lipo2000 5μL

[0268] Step (5) Virus infection: Human umbilical cord mesenchymal stem cells (cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee) were transduced with lentiviral concentrate to express FKBP-CASP9-2A-IFNβ1-IRES-GS.

[0269] Detection of IFNβ1 protein expression level. The expression of IFNβ1 protein was detected using an ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137), indicating that the prepared gene-modified human mesenchymal stem cells can successfully express FKBP-CASP9-2A-IFNβ1-IRES-GS.

[0270] Step (6) Screening of stable expression cell lines.

[0271] During the cell culture process of completed lentiviral gene transduction, glutamine-free medium was used, and 1000mM MSX was added to inhibit endogenous GS expression. The culture was maintained for 15 days, and intolerant cell death was observed. The surviving cells were passaged when the confluence reached 90-95%, and at least two generations of cells were cultured at a high concentration of MSX to meet the purification and screening of FKBP-CASP9-2A-IFNβ1-expressing cells, and then frozen for library construction, followed by long-term culture in 50mM MSX.

[0272] The target gene transduced in Example 1-8 and the obtained plasmid are specifically shown in Table 10.

[0273] Table 10 Target genes transduced in Example 1-8 and plasmids obtained

[0274]

[0275] Expression and functional assays

[0276] 1. Detection of human type I interferon in the culture supernatant of gene-modified human mesenchymal stem cells

[0277] The genetically modified human umbilical cord mesenchymal stem cells and the non-genetically modified human umbilical cord mesenchymal stem cells (HUC-MSC) provided in Example 1-8 were cultured at a rate of 6×10 5 The cells were inoculated in a six-well plate at an inoculum size of 1000 cells / well. After culturing for 24 h at 5% CO2, 37°C and saturated humidity, the culture supernatant was collected.

[0278] The ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.; catalog number: SP10137) was used to detect the content of human type I interferon (ng / mL) in the culture supernatant of each cell. The test results are shown in Table 11.

[0279] Table 11 Content of human type I interferon in the culture supernatant of each cell

[0280] Serial number Cell Type Human type I interferon content (ng / mL) Example 1 FKBP-CASP9-2A-IFNα2a 78 Example 2 FKBP-CASP9-2A-IFNα2b 109 Example 3 FKBP-CASP9-2A-IFNα2s 86 Example 4 FKBP-CASP9-2A-IFNβ1 64 Example 5 FKBP-CASP9-2A-IFNα2a-IRES-GS 561 Example 6 FKBP-CASP9-2A-IFNα2b-IRES-GS 657 Example 7 FKBP-CASP9-2A-IFNα2s-IRES-GS 831 Example 8 FKBP-CASP9-2A-IFNβ1-IRES-GS 326 Cells that have not been genetically modified HUC-MSC 0

[0281] As shown in Table 11, by comparing the genetically modified human umbilical cord mesenchymal stem cells provided in Examples 1-8 with the human umbilical cord mesenchymal stem cells that have not been genetically modified, it can be seen that the human umbilical cord mesenchymal stem cells modified by the suicide gene-type I interferon gene can efficiently express human type I interferon.

[0282] By comparing the human type I interferon content expressed by the genetically modified human umbilical cord mesenchymal stem cells provided in Examples 1-4 and Examples 5-8, it can be seen that by introducing the expression of the screening gene at the same time on the basis of the suicide gene-type I interferon gene modification, it is possible to screen out screening strains in which both the screening gene and the suicide gene-type I interferon gene are expressed at high levels and stably.

[0283] 2. Functional verification of suicide genes in genetically modified human mesenchymal stem cells

[0284] The genetically modified human umbilical cord mesenchymal stem cells and the non-genetically modified human umbilical cord mesenchymal stem cells (HUC-MSC) provided in Example 1-8 were cultured at a rate of 6×10 5 The inoculation amount of cells / well was inoculated in a six-well plate, and after culturing for 24 hours under 5% CO2, 37°C, and saturated humidity, 6nM AP1903 was added and cultured. After 24 hours, the cells of each group were digested and harvested, and the cell viability of each group was detected and recorded using a fluorescence counter (AO / PI mode), and compared with the cells before induction. Among them, cells expressing the FKBP-CASP9 suicide gene showed varying degrees of apoptosis. The test results are shown in Table 12.

[0285] Table 12 Validation data of suicide gene function of gene-modified human mesenchymal stem cells

[0286] Serial number Cell Type Cell viability (%) Example 1 FKBP-CASP9-2A-IFNα2a 41 Example 2 FKBP-CASP9-2A-IFNα2b 56 Example 3 FKBP-CASP9-2A-IFNα2s 49 Example 4 FKBP-CASP9-2A-IFNβ1 44 Example 5 FKBP-CASP9-2A-IFNα2a-IRES-GS 3 Example 6 FKBP-CASP9-2A-IFNα2b-IRES-GS 5 Example 7 FKBP-CASP9-2A-IFNα2s-IRES-GS 4 Example 8 FKBP-CASP9-2A-IFNβ1-IRES-GS 1 Cells that have not been genetically modified HUC-MSC (control group) 98

[0287] As can be seen from Table 12, by comparing the genetically modified human umbilical cord mesenchymal stem cells provided in Examples 1-8 with the human umbilical cord mesenchymal stem cells that have not been genetically modified, it can be seen that the human umbilical cord mesenchymal stem cells modified by the suicide gene-type I interferon gene all showed varying degrees of apoptosis, indicating that the suicide gene of the genetically modified human umbilical cord mesenchymal stem cells showed better suicide function.

[0288] By comparing the human type I interferon content expressed by the gene-modified human umbilical cord mesenchymal stem cells provided in Examples 1-4 and Examples 5-8, it can be seen that by introducing the screening gene on the basis of suicide gene-type I interferon gene modification, it is possible to screen out screening strains with high-level expression of the screening gene and high-level and stable expression of the type I interferon gene.

[0289] 3. Therapeutic effects of gene-modified human mesenchymal stem cells in mouse tumor models

[0290] The genetically modified human umbilical cord mesenchymal stem cells provided in Examples 5-8 and the non-genetically modified human umbilical cord mesenchymal stem cells (HUC-MSC) were used as test objects, and PBS was used as a control.

[0291] 1. Experimental mice

[0292] Thirty 8-week-old male C57BL / 6 mice were divided into 6 groups, each with 5 mice. Each group corresponded to the genetically modified human umbilical cord mesenchymal stem cells provided in Examples 5-8, the non-genetically modified human umbilical cord mesenchymal stem cells (control group), and PBS (control group).

[0293] 2. Test methods

[0294] B16 melanoma cells (10 5 On the 6th day after inoculation, after subcutaneous injection of sodium pentobarbital anesthesia, the corresponding human umbilical cord mesenchymal stem cells or non-genetically modified human umbilical cord mesenchymal stem cells (2×10 5 The tumor volume on the back of the mice was observed every three days, and the tumor volume was calculated and compared. The test results are shown in Table 13.

[0295] Table 13 Treatment of gene-modified human mesenchymal stem cells in mouse tumor models

[0296]

[0297] As shown in Table 13, the human umbilical cord mesenchymal stem cells after gene modification provided in Examples 5-8 are compared with human umbilical cord mesenchymal stem cells not after gene modification and PBS. It can be seen that the human umbilical cord mesenchymal stem cells after gene modification provided in this application have a good therapeutic effect on the mouse tumor model. Within 15 days, the tumor volume of mice treated with interferon gene modified human umbilical cord mesenchymal stem cells was significantly inhibited compared with the control group. Compared with the human mesenchymal stem cells with IFNβ1 gene provided in Example 8, the human mesenchymal stem cells with IFNα gene (IFNα2a gene, IFNα2b gene, IFNα2s gene) provided in Example 5-7 have better therapeutic effects.

[0298] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. A suicide gene-type I interferon expression vector, characterized in that: The expression vector comprises a suicide gene and a nucleotide sequence encoding type I interferon protein; the suicide gene and the nucleotide sequence encoding type I interferon protein are connected via a nucleotide sequence encoding a connecting peptide.

2. The suicide gene-type I interferon expression vector according to claim 1, characterized in that: The nucleotide sequence encoding type I interferon protein includes any one or more of the nucleotide sequences encoding IFNα protein and IFNβ protein.

3. The suicide gene-type I interferon expression vector according to claim 1, characterized in that: The suicide gene is any one or more of a nucleotide sequence encoding FKBP-CASP9 and a nucleotide sequence encoding HSVTK.

4. The suicide gene-type I interferon expression vector according to claim 1, characterized in that: The expression vector further comprises a screening gene, which is connected to the suicide gene and / or the nucleotide sequence encoding type I interferon protein via the nucleotide sequence encoding the connecting peptide; the screening gene is a nucleotide sequence encoding glutamine synthetase.

5. The suicide gene-type I interferon expression vector according to claim 4, characterized in that: The nucleotide sequence encoding glutamine synthetase can be replaced by a nucleotide sequence encoding an antibiotic resistance gene; the antibiotic resistance gene is any one or more of a puromycin resistance gene, a neomycin resistance gene, a hygromycin resistance gene and a blasticidin resistance gene.

6. The suicide gene-type I interferon expression vector according to claim 1, characterized in that: The nucleotide sequence encoding the connecting peptide is any one or more of the nucleotide sequences encoding P2A, T2A, E2A, F2A, and IRES.

7. The suicide gene-type I interferon expression vector according to claim 1, characterized in that: The front end of the nucleotide sequence encoding the type I interferon protein is immediately followed by a nucleotide sequence encoding a secretion signal peptide; the nucleotide sequence encoding the secretion signal peptide comprises the nucleotide sequence shown in SEQ ID NO 1.

8. A suicide gene-type I interferon expression vector according to any one of claims 1 to 7, used for virus packaging in a third-generation lentiviral packaging system, a second-generation lentiviral packaging system or an adeno-associated virus (AAV) packaging system.

9. Use of the suicide gene-type I interferon expression vector according to any one of claims 1 to 7 in human mesenchymal stem cells.

10. A genetically modified human mesenchymal stem cell, characterized in that: The human mesenchymal stem cells express any one or more of IFNα2a, IFNα2b, IFNα2s, and IFNβ1.

11. The genetically modified human mesenchymal stem cell according to claim 10, characterized in that: The human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a, FKBP-CASP9-2A-IFNα2b, FKBP-CASP9-2A-IFNα2s or FKBP-CASP9-2A-IFNβ1.

12. The genetically modified human mesenchymal stem cell according to claim 10, characterized in that: The human mesenchymal stem cells express FKBP-CASP9-2A-IFNα2a-IRES-GS, FKBP-CASP9-2A-IFNα2b-IRES-GS, FKBP-CASP9-2A-IFNα2s-IRES-GS or FKBP-CASP9-2A-IFNβ1-IRES-GS.

13. The genetically modified human mesenchymal stem cell according to claim 10, characterized in that: The human mesenchymal stem cells are one or more of human umbilical cord mesenchymal stem cells, human umbilical cord blood mesenchymal stem cells, human adipose mesenchymal stem cells, human bone marrow mesenchymal stem cells, human dental pulp mesenchymal stem cells, human placenta mesenchymal stem cells, and human uterine blood mesenchymal stem cells.

14. Use of the genetically modified human mesenchymal stem cells according to any one of claims 10 to 13 in the preparation of a drug for treating solid tumors.

15. The use according to claim 14, characterized in that: The solid tumor includes any one or more of melanoma, colon cancer, ovarian cancer, glioma, pancreatic cancer, breast cancer, prostate cancer, gastric cancer, liver cancer, lung cancer, and kidney cancer.